ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
Two positive events in January support PMN310 “best in class” positioning
TORONTO and CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its perspectives on recent progress in the Alzheimer’s field.
Two important events occurred in January 2021, both of which we consider very positive for the Alzheimer’s field, for the updated amyloid hypothesis, and for ProMIS Neurosciences. The FDA extended the PDUFA date (Prescription Drug User Fee Act) for review of Biogen’s aducanumab from March 7 to June 7, 2021, as announced on January 29. Lilly announced positive clinical results for their antibody, donanemab, on January 11, making it the